Seek Labs Expands Veterinary Therapeutic⁤ Progress, Targeting Global Livestock Threats

in today’s rapidly ‌evolving global health⁣ landscape, the interconnectedness of human and ​animal​ well-being has never been more apparent. As we navigate the complexities of emerging‍ diseases and the persistent threats to our ⁣food supply, ⁢innovative solutions are paramount. Seek Labs, a leader in developing programmable therapeutics and diagnostics, is stepping up to ⁤meet⁤ these challenges head-on. their recent ⁤expansion into veterinary therapeutic development, focusing on high-outcome livestock ‍pathogens, marks a meaningful ⁤stride in their mission to protect global health.

“We are thrilled to expand our Programmable Target ablation Platform (PTAP) capabilities to⁤ address critical veterinary needs,” said Douglas Gladue,Seek Labs’ VP of ‌Veterinary Pharmaceutical Development. This strategic move underscores Seek Labs’ commitment to a holistic approach to health, recognizing that safeguarding animal populations is intrinsically linked to human health and global food security.

tackling Devastating Livestock Diseases with Precision

The economic and social impact of livestock diseases is staggering.These outbreaks not ⁤only threaten animal welfare but also have profound implications ⁤for economies, food security, ⁤and international trade. Seek Labs is leveraging its cutting-edge BioSeeker™​ platform and PTAP™ to develop novel solutions‌ for some ‍of the moast pressing veterinary challenges.

Capripox Viruses (Lumpy Skin Disease, Sheep⁢ and Goat Pox)

Capripox viruses represent a significant global threat to livestock. These highly contagious pathogens, including Lumpy Skin Disease (LSD), Sheep Pox, and Goat pox, have caused devastating outbreaks across continents. The cumulative losses over the past decade are estimated to exceed $1 billion globally. These losses stem from various factors, ‌including ⁢the necessary culling⁤ of ‌infected animals, the imposition of trade bans that disrupt markets, and ⁢significant declines in livestock production.

What makes these⁣ viruses particularly challenging is‍ their close genetic relationship.Belonging to the same viral ​family, Capripox, ‌they share highly conserved genomic regions. This genetic similarity presents a unique prospect for therapeutic intervention.Seek​ Labs, through its⁣ BioSeeker™ platform, has identified specific ⁤targets⁢ within these conserved regions. These identified targets are crucial for supporting the development of a potential pan-Capripox therapeutic. Such⁤ a therapeutic would be designed to‌ combat outbreaks across diverse geographical⁢ regions, offering a unified‍ approach to a multifaceted problem.

The development of a pan-Capripox therapeutic⁢ is a game-changer. It means that a ⁢single,adaptable⁤ treatment could potentially address ⁢multiple strains of the virus,simplifying response efforts and reducing the time and ‌resources needed to combat outbreaks.This precision targeting ensures that the therapeutic ‍can effectively neutralize the virus while minimizing off-target effects, ‌a hallmark of Seek Labs’ ⁤programmable approach.

Classical Swine‍ Fever (CSFV)

Classical‌ Swine fever ‌(CSFV) is another‍ formidable transboundary threat that continues to plague the global swine industry. This disease is characterized by ‌its persistence and high contagiousness,making it incredibly difficult to control once it enters a susceptible population. The economic toll of CSFV⁤ has been ⁢immense, with‍ estimated global losses in recent decades reaching over $5 billion. These staggering figures are a direct‌ result of the extensive trade restrictions imposed to prevent its spread, the widespread culling of infected herds to ⁤contain outbreaks, and the costly, long-term eradication ⁢campaigns that often follow.

The persistent nature of CSFV means that even after successful eradication efforts, the virus‌ can lie dormant or re-emerge, posing a continuous risk. The economic impact is not limited to direct losses from animal ⁢deaths;‍ it extends to the disruption of supply chains,⁤ the loss of‍ export markets, and the significant investment required for biosecurity measures ​and surveillance.

Seek Labs’ ability to develop programmable‌ solutions for CSFV highlights the versatility of their PTAP™ platform.By ⁤precisely targeting conserved vulnerabilities within the CSFV genome, they​ aim to create therapeutics that can rapidly and effectively neutralize the virus.this approach⁤ offers a more lasting and less disruptive choice to traditional methods like ‌mass culling, which have significant ethical and economic consequences.

The cross-species capability demonstrated by Seek Labs in addressing both Capripox viruses​ and CSFV is particularly noteworthy. It showcases their capacity to ​rapidly design, develop, and ⁣deliver programmable solutions⁤ that can tackle diverse, high-consequence threats. This not only strengthens animal health infrastructure but also significantly bolsters global bio-surveillance and ‍control⁣ efforts, creating a​ more resilient system against zoonotic‌ and transboundary diseases.

Partnering for a Holistic​ Global ​Health Solution

Seek Labs’ commitment to global health extends ⁢beyond human medicine.The inclusion of veterinary pathogens in their development pipeline is a clear recognition of the critical ‌interdependence between human and animal health. This “One Health” approach‌ is essential for building a truly thorough global health strategy.By building a⁤ robust, partner-ready repository of ⁣mapped genomic targets, Seek ​Labs is creating a valuable resource for the scientific and veterinary communities. This repository,combined with the ⁢precision mapping ​capabilities of​ BioSeeker™ and the adaptable nature ​of their Programmable ‍Target ablation ‌Platform ⁣(PTAP™),offers partners an efficient and accelerated path to advance next-generation veterinary therapeutics.

Seek Labs actively seeks qualified partners who share their vision for ‍improving global health outcomes. ‍By collaborating, they aim to deliver transformative solutions that not only enhance ⁢animal welfare ​but ⁣also strengthen global food security infrastructure. The market for advanced veterinary therapeutics is growing rapidly, driven by increasing awareness of disease risks and the​ demand for sustainable agricultural practices. Seek labs is positioning itself at the forefront of this market,offering innovative solutions that address urgent‍ needs.

The company’s‍ approach⁣ is ⁤designed to⁤ be highly‍ collaborative.‍ They understand that tackling complex global health challenges requires a collective effort. By providing their proprietary technology and expertise, Seek Labs empowers partners to accelerate their own development pipelines, bringing⁤ much-needed therapies to ⁤market faster. This partnership model⁤ is crucial for maximizing impact and ensuring that these advanced ⁤solutions reach​ the animals and communities⁢ that need them most.

About Seek Labs: Building the Future ‌of Health⁢ Intervention

Seek Labs operates with a proactive beliefs: “We don’t wait for change-we build it.” This ethos drives their pursuit of breakthroughs that the world cannot afford to wait for. Their core mission revolves around developing programmable “seek-and-destroy”‍ therapeutics and point-of-care molecular diagnostics.these innovations are designed to significantly shorten the gap between the emergence of an outbreak and the implementation of effective intervention.

At the heart of Seek Labs’ operational model is a sophisticated, layered architecture. This architecture ensures a seamless integration of intelligence gathering,​ target identification, ⁤and‍ therapeutic deployment.

The Intelligence Layer: This layer ⁢is powered by BioSeeker™. BioSeeker™ is continuously engaged⁣ in mapping conserved viral vulnerabilities in real-time. This ongoing intelligence gathering⁣ is crucial for staying ahead of evolving pathogens and identifying novel therapeutic ‍targets.
The Deployment Layers: The insights generated by BioSeeker™ activate the Deployment Layers. These include PTAP™ for programmable therapeutics and SeekIt™ for molecular‍ diagnostics. Together,‌ these components form a full-stack ⁢development engine. this engine is specifically engineered⁢ to accelerate response times, foster innovation, and maximize impact across⁢ the spectrum of global health challenges.

Seek Labs is headquartered ‌in Salt Lake City and is ‌a proud member of BioHive, Utah’s vibrant and collaborative life sciences ecosystem. This ⁣supportive surroundings fosters innovation and facilitates partnerships,enabling Seek Labs⁢ to​ push the boundaries of what’s possible in health technology. By working together with​ their partners, Seek Labs is dedicated to building faster, smarter solutions for the world’s most urgent health challenges, both ‍human and animal.

Forward-Looking Statements and Regulatory disclaimer

This press release⁢ contains forward-looking statements regarding seek⁢ Labs’ technologies, development plans, and partnership‍ opportunities. These⁤ statements are based on current expectations and are subject to various​ risks and uncertainties that could cause ‍actual results to differ materially. The technologies described herein are investigational and have not been reviewed or approved‌ by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for clinical or commercial use.

Connect with Seek ‍Labs

Seek Labs is actively seeking⁤ collaborations to advance its mission. For inquiries regarding partnerships or to learn more about their innovative technologies, please reach out to:

Bridget Baldwin
Director of Communications
communications@seeklabs.com

The future of global health security ⁢relies on ​innovation,collaboration,and a ​proactive approach to emerging threats. Seek Labs is at the forefront, developing‍ the tools and therapies needed to protect both human and animal populations, ensuring a healthier and more secure world for generations to come.